Treatment of Bolivian L Braziliensis Mucosal Leishmaniasis with Inhaled Pentamidine Plus Oral Miltefosine

February 24, 2025 updated by: Jaime Soto, Fundacion Nacional de Dermatologia
This is a phase 2 study of the combination of inhaled-pentamidine plus oral miltefosine for Bolivian mucosal leishmaniasis.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The 3 major forms of leishmaniasis are visceral, cutaneous, and mucosal disease. Of these, mucosal leishmaniasis (ML) arguably poses the most difficult therapeutic problem. Although visceral disease (VL) occurs in perhaps 300,000 persons a year and is rapidly fatal since TH1 immunity is lacking, visceral disease is well-treated by drugs. Whereras cutaneous disease (CL) is the most prevalent major form occurring in perhaps 1,000,000 persons a year, TH1 Immunity is present and CL self-resolves in 3-18 months.

CL is treated to speed healing of the cutaneous lesion and, for certain species, to try to prevent dissemination of parasites to the oro-nasal mucosa resulting in mucosal leishmaniasis .

Mucosal leishmaniasis (ML) is estimated to occur as a late sequella in approximately 3% of L braziliensis CL. If there are approximately 130,000 cases per year of L braziliensis cutaneous disease, and 3% of these are succeeded by ML, the approximately 4,000 yearly cases of L braziliensis ML makes ML far less common than VL or CL. However, and in spite of more TH1 immunity than cutaneous disease, self-cure of ML is so rare as to be reportable. The patient with ML experiences inexorable erosion of the cartilage of the nose, pharynx, palate, and larynx. ML has been difficult to treat with classical agents (a cure rate of approximately 71%) Thus, of the 3 common forms of leishmaniasis, ML is the form that combines disease severity with poor response to chemotherapy.

Mucosal disease is perhaps the most chemotherapeutically challenging presentation of the leishmaniases. Unlike cutaneous disease, ML results in significant medical morbidity leading to marked psycho-social difficulty, and even mortality. Unlike visceral disease which although mortal quickly responds to therapy, ML is difficult to cure and relapses are common.

Drug combinations are now accepted approaches for many infectious diseases. Since 2 drugs already have the disadvantages of increased cost and potential increased toxicity, use of non-parenteral agents is an important consideration for any proposed combination. As the only recognized oral antileishmanial agent, miltefosine is the drug on which antileishmanial combinations have been based for visceral disease and for cutaneous disease [thermotherapy plus miltefosine: Soto personal communication].

The goal for a miltefosine-based combination for ML would be to raise the ML miltefosine cure rate for "mild" nasal disease to >90% and to raise the miltefosine cure rate for anatomically extensive disease to >58%. Inhaled pentamidine is a non-parenteral agent which in our pilot study was very successful for mild disease (86% cure) but unsuccessful for moderate or severe disease. The combination of oral miltefosine and inhaled pentamidine is a completely non-parenteral regimen that should lead to >90% cure of mild ML disease and could lead to an improved cure rate of moderate-severe disease. Although two drugs will be administered, adverse events should not be additive because miltefosine does not affect the respiratory tract and inhaled pentamidine is minimally absorbed.

This proof-of-concept phase 2 trial will enroll 20 moderate-to-severe ML patients. The primary endpoint is the cure rate for moderate-severe patients in comparison to literature values for miltefosine alone. If mild ML patients present, up to 10 will also be enrolled. The secondary endpoint is demonstrating that the cure rate for mild disease is 90%-100%.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Bolivia
      • La Paz, Bolivia, 00000
        • Recruiting
        • Hospital de Clínicas
        • Contact:
          • Sandra Encinas, MD
          • Phone Number: 76764100

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Gender: Male or female
  • Age: >12 yrs of age
  • Weight: > 45 kg
  • Consent: Prior to any investigations
  • Mucosal disease: Involvement of the nares, nasal mucosa, palate, pharynx, larynx according to the ENT specialist.
  • Parasitology: Parasitological confirmation of the lesion (s) will be made by visualization of Leishmania, culture of Leishmania, or molecular identification of Leishmania (PCR) from the biopsy or aspirate of the lesion (s); or a positive Leishmanin skin test plus a scar characteristic of cutaneous leishmaniasis, plus the epidemiologic antecedent of living now or in the past, in an endemic area.

Exclusion Criteria:

  • Previous treatment for leishmaniasis: No specific or putatively specific therapy (Sb, pentamidine, amphotericin B, miltefosine, imidazoles, allopurinol) in the last 12 months. Patients may have been previously treated with the agents under investigation---miltefosine, pentamidine---if that treatment ended more than 12 months ago and the disease has not diminished in the last 6 months.
  • Other diseases: Concomitant diseases by history that would be likely in the PI's opinion to interact, either positively or negatively, with treatment.
  • Laboratory : Values of complete blood count, liver function (AST, ALT, alkaline phosphatase), renal function (creatinine, BUN), pancreatic function (lipase), or uric acid beyond 1.5 x Normal Range and that in the PI's opinion would be clinically meaningful.
  • EKG: Clinically significant abnormalities.
  • Contraception: Women of childbearing age are required to practice reproductive contraception for 5 months after initiating therapy: abstinence or effective contraception defined as 2 forms of contraception [a barrier method (diaphragm, condom, or cervical cap with spermicidal foam, gel, or cream) plus a 2nd barrier method or hormonal contraceptive or intrauterine device] from day 1 through 5 months post therapy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Subjects treated
Miltefosine TID for 28 days Inhaled pentamidine 300 mg on days 1,3,5,8,10,12,15,17,19,22
Drug: Miltefosine Oral Capsule
Miltefosine 3 pill per day during 28 days AND pentamidine inhaled 300 mg / d during 10 dosis
Other Names:
  • Pentamidine isethionate inhaled

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Efficacy
Time Frame: 25 months
Clinical Score.Qualification compromise in five places (nose skin, nose mucosa, mouh-palate mucosa, pharynx and larynx usind four signs ( erythema, inflamation, infiltration and ulceration) with this scale: 0= absen5t, 1=mild, 2= moderate and 3= severe. Maximun score: 60
25 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Treatment-Emergent Adverse Events
Time Frame: 6 months
as Measured by the Number of Adverse Drug Reactions. Physical examination data will be listed at screening and at follow up time points. For laboratory data, the values that are below the lower limit or above the upper limit of the normal reference range will be flagged. Those values or changes in values, which are identified as being clinically significant, will be flagged and summarized separately. For physical examination data, any clinically relevant changes
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fundacion Nacional de Dermatologia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 4, 2025

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

February 1, 2028

Study Registration Dates

First Submitted

August 8, 2024

First Submitted That Met QC Criteria

August 8, 2024

First Posted (Actual)

August 13, 2024

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 24, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ABF-BO-100-10

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mucosal Leishmaniasis

Clinical Trials on Miltefosine Oral Capsule

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe